Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Stoke Therapeutics, Inc.
STOK
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.0B
$32.70
▼ -0.03%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$11.36 - $40.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 183.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary TANGO RNA technology
- Targeted antisense oligonucleotide platform
- Focus on rare genetic neurological disorders
- Strategic collaboration with Acadia Pharmaceuticals
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Advancing clinical trials for STK-001
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-0.1% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying STOK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 12, 2026
MAY 7, 2026
Reported EPS of -$0.79 vs -$0.80 consensus (+1.3% surprise). Revenue of $6.2M vs $6.5M expected (-3.9%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+1.3%
Next: May 12, 2026
Revenue trend · last 8Q
—
—
+707%
—
+186%
+117%
-94%
-96%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$4.8M
$4.9M
$22.6M
$158.6M
$13.8M
$10.6M
$1.4M
$6.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-802.8%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: BTIG · May 11, 2026